Table 2 Potential role of intralesional monotherapy
From: Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016
Yes | No |
|---|---|
Not all patients are candidate for systemic therapy (co-morbidities, toxicity) | Systemic therapies in 2015 are safe and effective |
After progression on other therapies | Melanoma is a systemic disease |
Alternative to surgery? | Surgery is an instant CR |
Neoadjuvant potential | Not yet proven |